Table 1 Demographic and clinical data for the PD participants in the LRRK2 Ashkenazi Jewish cohort
Baseline | +2 years | 2 years - baseline | |
|---|---|---|---|
N | 122 | 67 | |
Age | 70.4 ± 0.8 (49–90) | 71.1 ± 1 (50–89) | |
Sex (M/F) | 75/47 | 46/21 | |
Age at diagnosis | 58.4 ± 0.9 (34–83) | 58.5 ± 1.2 (34–83) | |
LRRK2 G2019S (N/Y) | 57/61 | 34/29 | |
GBA1 (N/Y) | 94/3 | 48/2 | |
LRRK2/GBA1 (N/Y) | 93/4 | 63/4 | |
LED | 560.3 ± 38.5 (0–2280) | 707.6 ± 56.1 (0–2600)* | |
MoCA | 25.1 ± 0.4 (5–30) | 25.15 ± 0.5 (10–30) | −0.8 ± 0.4 |
UPDRS III | 22.7 ± 1.2 (2–67) | 25.4 ± 1.7* (1–71) | 3.6 ± 1.1 |
Epworth Sleep | 8.7 ± 0.4 (0–22) | 9.4 ± 0.6 (1–24) | 0.2 ± 0.6 |
Depression | 4.2 ± 0.4 (0–14) | 4.5 ± 0.5* (0–15) | 0.9 ± 0.4 |
Activities of Daily Living | 76. 7 ± 2 (10–100) | 72.9 ± 2.4** (20–100) | −7.5 ± 2 |
SCOPA-AUT | 22.6 ± 1.2 (0–62) | 24.6 ± 1.5 (4–52) | 1.7 ± 1.8 |
REM sleep | 3.9 ± 0.3 (0–12) | 3.7 ± 0.4 (0–12) | −0.5 ± 0.3 |
UPSIT | 20.8 ± 0.9 (2–39) | 17.5 ± 1* (7–39) | −1.3 ± 0.8 |
Hoehn & Yahr | 2.4 ± 0.1 (0–5) | 2.7 ± 0.1* (1–5) | 0.5 ± 0.1 |
NfL | 126.6 ± 30.8 pg/ml | ||
α-synuclein | 17.9 ± 2.3 ng/ml |
